- Home
- USLM vs IBRX Comparison
USLM vs IBRX Comparison
Compare USLM & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USLM
- IBRX
- Stock Information
- Founded
- USLM 1948
- IBRX 2014
- Country
- USLM United States
- IBRX United States
- Employees
- USLM N/A
- IBRX N/A
- Industry
- USLM Other Metals and Minerals
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- USLM Industrials
- IBRX Health Care
- Exchange
- USLM Nasdaq
- IBRX Nasdaq
- Market Cap
- USLM 2.9B
- IBRX 2.3B
- IPO Year
- USLM N/A
- IBRX N/A
- Fundamental
- Price
- USLM $104.62
- IBRX $2.79
- Analyst Decision
- USLM
- IBRX Strong Buy
- Analyst Count
- USLM 0
- IBRX 5
- Target Price
- USLM N/A
- IBRX $11.40
- AVG Volume (30 Days)
- USLM 215.5K
- IBRX 8.0M
- Earning Date
- USLM 07-30-2025
- IBRX 08-11-2025
- Dividend Yield
- USLM 0.23%
- IBRX N/A
- EPS Growth
- USLM 50.52
- IBRX N/A
- EPS
- USLM 4.20
- IBRX N/A
- Revenue
- USLM $337,287,000.00
- IBRX $31,222,000.00
- Revenue This Year
- USLM $21.67
- IBRX $567.98
- Revenue Next Year
- USLM $13.19
- IBRX $160.56
- P/E Ratio
- USLM $24.84
- IBRX N/A
- Revenue Growth
- USLM 17.83
- IBRX 10238.41
- 52 Week Low
- USLM $65.45
- IBRX $1.83
- 52 Week High
- USLM $159.53
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- USLM 58.23
- IBRX 50.75
- Support Level
- USLM $100.04
- IBRX $2.68
- Resistance Level
- USLM $105.80
- IBRX $3.00
- Average True Range (ATR)
- USLM 3.60
- IBRX 0.16
- MACD
- USLM 0.47
- IBRX -0.02
- Stochastic Oscillator
- USLM 89.98
- IBRX 58.00
About USLM United States Lime & Minerals Inc.
United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. It supplies its products predominantly to the construction (including highway, road, and building contractors), industrial (including paper and glass manufacturers), environmental (including municipal sanitation and water treatment facilities and flue gas treatment processes), metals (including steel producers), oil and gas services, roof shingle manufacturers and agriculture (including poultry and cattle feed producers) industries. The company operates through its Lime and Limestone Operations segment.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.